NYU Finance Professor Damodaran Values Anthropic at $1.475 Trillion, Below IPO Pricing Range
Damodaran performs an intrinsic valuation of Anthropic based on its recently filed S-1 prospectus with the U.S. Securities and Exchange Commission (SEC). Assuming revenues reach $1 trillion by 2036, an operating margin of 27.5%, a capital requirement of $1 for every $3 in incremental revenue, and a cost of capital of 9.74%, he derives an equity value of $1.475 trillion. This figure sits at the lower end of the IPO pricing range ($1.5 to $2 trillion). He also presents a worst-case scenario (negative equity value of $373 billion) and a best-case scenario ($4.04 trillion), emphasizing that investors must make their own decisions based on their own narratives and valuations, not his.
Damodaran’s equity valuation for Anthropic stands at $1.475 trillion—just below the IPO pricing range of $1.5 to $2 trillion. This number itself is not the conclusion; rather, the conclusion lies in the four assumptions used to derive it, along with his repeated insistence on one key point: these represent his story, and your investment decisions must stem from your own story and valuation, not his.
On October 26, 2026, Anthropic filed its S-1 registration statement with the U.S. Securities and Exchange Commission (SEC). Damodaran completed his valuation two days later. His starting point was not a pricing multiple but a fundamental judgment: a prospectus is a document rooted in the past, while a company’s value lies in your expectations for the future. He breaks his valuation into four narrative threads—revenue growth, profitability, reinvestment needs, and risk—providing his choices for each while leaving room for readers to adjust them.
On the revenue front, Damodaran notes that Anthropic’s income in the first two quarters of 2026 was approximately fourteen times higher than in the same period of 2025. However, growth significantly slowed in the third quarter due to OpenAI gaining market share, compute capacity becoming a bottleneck, and some enterprises shifting to cheaper open-source models. His assessment is that the total addressable market for AI products and services could exceed $5 trillion, with Anthropic targeting the premium segment and appearing to be the leader in that niche. Based on this, he assumes Anthropic’s revenues could approach $1 trillion by 2036. He points out that no company currently generates more than $1 trillion in revenue globally, with Amazon and Walmart sitting around $700 to $750 billion.
Regarding profitability, Anthropic reported an $80 billion loss for the first half of the year, but $72 billion of this was a non-cash charge related to the expensing of convertible bond options. After adjusting for this, the actual operating loss exceeded $8 billion. The positive trend is improving: the company claims it achieved operating profit in the most recent quarter, and expense ratios as a percentage of revenue continue to decline, with compute costs dropping from over 250% of revenue to 48%. Damodaran assumes Anthropic’s final revenue mix will be 75% from premium products and 25% from the mass market, corresponding to an unadjusted pre-tax operating margin of 32.5%. After deducting 5 percentage points for regulatory impacts, he arrives at a target margin of 27.5%.
The reinvestment thread involves Anthropic’s compute commitments exceeding $600 billion. Damodaran notes that these investments currently do not appear as capital expenditures in the cash flow statement or as debt and invested capital on the balance sheet, but the company has not hidden them—the prospectus explicitly lists hundreds of billions in future compute contracts. His assumption is that $1 of capital is required for every $3 of incremental revenue, consistent with current technology companies’ revenue per dollar of invested capital. However, given Anthropic’s expected revenue leap, this translates into massive annual dollar reinvestments. While chip costs may fall, new models may demand proportionately more compute power, and data centers face community opposition that could drive up costs.
The risk thread is divided into three layers. On operational risk, he estimates a cost of capital of 9.74%, which is higher than the September 2026 median of 9.16% for U.S. companies but lower than the third quartile of 9.88%. On financing risk, he acknowledges that the BB+ bond rating and hundreds of billions in contractual commitments create default risk, but argues that the $114 billion cash balance, combined with an estimated $100 billion from the IPO proceeds and the ability to raise capital as a high-market-cap public company, will suppress failure probability. He estimates a 10% probability of failure, resulting in a loss of half the company's value if it occurs. On regulatory risk, he believes the impact will be mild, having already reduced the margin estimate from 32.5% to 27.5%.
Combining the four narrative threads yields an equity value of $1.475 trillion. However, Damodaran deliberately presents a range: In the worst-case scenario—target revenues stagnate at only $200 billion, margins converge to the mass market level of 10%, compute remains scarce and expensive (yielding only $1 of revenue per dollar of capital), the cost of capital rises to 9.88%, and regulatory impacts are severe—the equity value is negative $373 billion, meaning the company cannot survive as a going concern. In the best-case scenario—revenues surge to $1.5 trillion, margins reach 40%, compute becomes cheap (yielding $4 of revenue per dollar of capital), the cost of capital drops to 7.79%, and there is no regulatory impact—the equity value reaches $4.04 trillion.
Damodaran advises readers to use what he calls the 3P test to evaluate their own stories: Is it Possible? Is it Plausible? Is it Probable? He believes both the best and worst cases are possible but unlikely. Investors should base their decisions on their own judgments. He explicitly states that he will be wrong 100% of the time; this is not humility but a methodological statement: valuation is essentially a translation of future assumptions, and different people should arrive at different numbers.
On corporate governance, Damodaran’s tone is unusually sharp. Anthropic has issued five classes of stock with different voting rights. Founders control 50.1% of the voting power through a benefit trust, ensuring their control is never diluted regardless of future share issuances. The company is also registered as a Public Benefit Corporation (PBC). The prospectus explicitly states it can make decisions that balance the pecuniary interests of stockholders with broader societal interests, even if those decisions negatively impact financial returns. Damodaran argues this goes further than the dual-class structures of Alphabet and Meta. The combination of a PBC structure and five voting classes gives management legal license to use shareholder funds for almost any purpose.
Regarding trading strategy, Damodaran says he will wait for the IPO pricing result. If the price is significantly above his $1.48 trillion valuation, he will sit on the sidelines. He will not short the stock because, although he has confidence in his valuation, he has no reason to believe the market will agree with him. Even if the market is wrong, it may not correct within his time horizon. He cites Facebook as an example: in June 2012, he judged the $36 IPO price to be overvalued, but when the stock fell to $18 three months later, he became a buyer. He believes Anthropic’s governance structure requires a larger discount, but the market may provide that discount as well.